C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces that at the General Meeting held earlier today, all the resolutions put to shareholders were duly passed.
Calculus Capital Limited and Polar Capital LLP to join share register
C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery engine, today announces that it has raised £5.0 million before expenses (the "Placing") via a conditional placing of 4,901,961 new ordinary shares (the "Placing Shares") to current and new investors, through Zeus Capital as nominated adviser and broker to the Company, at a placing price of 102p (the “Placing Price”) per ordinary share.
Proprietary platform technology further augments C4X Discovery’s drug discovery engine
12th July, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces the acquisition of a suite of advanced drug-discovery technologies from MolPlex Ltd (the "Molplex Technologies").
~ Rapid progress with drug discovery portfolio and ground-breaking findings in inflammation and neurodegeneration ~
4th July, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces the identification of multiple new drug targets in the areas of inflammation and neurodegeneration.
4th May, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces that Clive Dix has been appointed Chief Executive Officer with immediate effect.
17 March, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces its interim unaudited results for the six months ended 31 January 2016.
1 March, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces the acquisition of Adorial Limited together with its subsidiaries ("Adorial"), a privately held drug discovery company with a proprietary genetic technology platform for the identification of novel drug targets ("the Acquisition").
19 November, 2015 – C4X Discovery Holdings plc (“C4XD” or the “Company”), a leader in rational drug discovery and design, today announces the appointment of Dr Clive Dix as Executive Chairman.